194 related articles for article (PubMed ID: 29592893)
1. Recurrent
Sharma A; Oishi N; Boddicker RL; Hu G; Benson HK; Ketterling RP; Greipp PT; Knutson DL; Kloft-Nelson SM; He R; Eckloff BW; Jen J; Nair AA; Davila JI; Dasari S; Lazaridis KN; Bennani NN; Wu TT; Nowakowski GS; Murray JA; Feldman AL
Blood; 2018 May; 131(20):2262-2266. PubMed ID: 29592893
[No Abstract] [Full Text] [Related]
2. Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract.
Hu G; Phillips JL; Dasari S; Jacobs HK; Luchtel RA; Oishi N; Hundal T; Ahmed NH; Satou A; Epstein AL; Bennani NN; Nowakowski GS; Murray JA; Feldman AL
Leukemia; 2020 May; 34(5):1467-1471. PubMed ID: 31836854
[No Abstract] [Full Text] [Related]
3. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract.
Perry AM; Warnke RA; Hu Q; Gaulard P; Copie-Bergman C; Alkan S; Wang HY; Cheng JX; Bacon CM; Delabie J; Ranheim E; Kucuk C; Hu X; Weisenburger DD; Jaffe ES; Chan WC
Blood; 2013 Nov; 122(22):3599-606. PubMed ID: 24009234
[TBL] [Abstract][Full Text] [Related]
4. Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract.
Soderquist CR; Patel N; Murty VV; Betman S; Aggarwal N; Young KH; Xerri L; Leeman-Neill R; Lewis SK; Green PH; Hsiao S; Mansukhani MM; Hsi ED; de Leval L; Alobeid B; Bhagat G
Haematologica; 2020 Jul; 105(7):1895-1906. PubMed ID: 31558678
[TBL] [Abstract][Full Text] [Related]
5. Oral manifestation of indolent T-cell lymphoproliferative disorder of the gastrointestinal tract: A potential diagnostic pitfall.
Saggini A; Baciorri F; Di Prete M; Zizzari AG; Anemona L
J Cutan Pathol; 2020 May; 47(5):494-496. PubMed ID: 32003865
[No Abstract] [Full Text] [Related]
6. Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas.
Montes-Moreno S; King RL; Oschlies I; Ponzoni M; Goodlad JR; Dotlic S; Traverse-Glehen A; Ott G; Ferry JA; Calaminici M
Virchows Arch; 2020 May; 476(5):667-681. PubMed ID: 31773249
[TBL] [Abstract][Full Text] [Related]
7. JAK2 and STAT3 polymorphisms in a Han Chinese population with Behçet's disease.
Hu K; Hou S; Jiang Z; Kijlstra A; Yang P
Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):538-41. PubMed ID: 22205606
[TBL] [Abstract][Full Text] [Related]
8. An unusual case report of indolent T-cell lymphoproliferative disorder with aberrant CD20 expression involving the gastrointestinal tract and bone marrow.
Wang X; Ng CS; Chen C; Yu G; Yin W
Diagn Pathol; 2018 Oct; 13(1):82. PubMed ID: 30342536
[TBL] [Abstract][Full Text] [Related]
9. Indolent T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: a review and update.
Matnani R; Ganapathi KA; Lewis SK; Green PH; Alobeid B; Bhagat G
Hematol Oncol; 2017 Mar; 35(1):3-16. PubMed ID: 27353398
[TBL] [Abstract][Full Text] [Related]
10. [Expression and Clinical Significance of Peripheral Blood T cell JAK2/STAT3 mRNA in Chronic Idiopathic Thrombocytopenic Purpura].
Song L; DU NC; Li FR; Liu F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1746-1751. PubMed ID: 30501715
[TBL] [Abstract][Full Text] [Related]
11. Indolent T-cell lymphoproliferative disorder of gastrointestinal tract with unusual clinical courses: report of 6 cases and literature review.
Fan W; Niu L; He H; Yuan J; Yuan F; Shi X; Wang Y; Chen M; Huang M; Zhou F; Xu J; Chen Q
Virchows Arch; 2023 Apr; 482(4):729-743. PubMed ID: 36472661
[TBL] [Abstract][Full Text] [Related]
12. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A
Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672
[TBL] [Abstract][Full Text] [Related]
13. Contribution of JAK2 and STAT3 variants to the genetic susceptibility of recurrent spontaneous miscarriage in a Tunisian population.
Messaoudi S; Hizem S; Al-Sulaiti MA; Al-Busaidi AS; Magdoud K; Dendana M; Almawi WY; Mahjoub T
Genet Test Mol Biomarkers; 2013 Jan; 17(1):35-9. PubMed ID: 23193966
[TBL] [Abstract][Full Text] [Related]
14. 15-Lipoxygenase-1-enhanced Src-Janus kinase 2-signal transducer and activator of transcription 3 stimulation and monocyte chemoattractant protein-1 expression require redox-sensitive activation of epidermal growth factor receptor in vascular wall remodeling.
Singh NK; Wang D; Kundumani-Sridharan V; Van Quyen D; Niu J; Rao GN
J Biol Chem; 2011 Jun; 286(25):22478-88. PubMed ID: 21536676
[TBL] [Abstract][Full Text] [Related]
15. AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers.
Katsha A; Arras J; Soutto M; Belkhiri A; El-Rifai W
Mol Oncol; 2014 Dec; 8(8):1419-28. PubMed ID: 24953013
[TBL] [Abstract][Full Text] [Related]
16. VITREORETINAL INVOLVEMENT BY INDOLENT T-CELL LYMPHOPROLIFERATIVE DISORDER OF THE GASTROINTESTINAL TRACT DIAGNOSED BY FLUORESCENCE IN SITU HYBRIDIZATION.
Salman AR; Ferenchak K; Olsen TW; Smith WM; Ketterling RP; McPhail ED; Salomao DR; Dalvin LA
Retin Cases Brief Rep; 2023 Sep; 17(5):572-576. PubMed ID: 37490925
[TBL] [Abstract][Full Text] [Related]
17. Lymphoproliferative Disorders of the Gastrointestinal Tract.
Skinnider BF
Arch Pathol Lab Med; 2018 Jan; 142(1):44-52. PubMed ID: 28829152
[TBL] [Abstract][Full Text] [Related]
18. Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway.
Quesada AE; Zhang Y; Ptashkin R; Ho C; Horwitz S; Benayed R; Dogan A; Arcila ME
Breast J; 2021 Apr; 27(4):314-321. PubMed ID: 33660353
[TBL] [Abstract][Full Text] [Related]
19. Indolent Lymphoproliferative T-Cell Disorders Associated With Gastrointestional Disease: Diagnostic Challenges and Outcomes.
Masciopinto P; Bellitti E; Arcuti E; Battisti O; Cazzato G; Perrone T; Longo MC; Laddaga FE; Maiorano E; Musto P; Ingravallo G; Gaudio F
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e745-e750. PubMed ID: 35501257
[TBL] [Abstract][Full Text] [Related]
20. Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations.
Yang HS
Cancer Biomark; 2016; 17(4):383-389. PubMed ID: 27662324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
